Role of Methotrexate in the Treatment of Bullous Pemphigoid in the Elderly

Authors: Patton, Timothy¹; Korman, Neil²

Source: Drugs & Aging, Volume 25, Number 8, 2008 , pp. 623-629(7)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Bullous pemphigoid (BP) is an autoimmune blistering disease that commonly occurs in the elderly. Immunosuppressive medications are effective at controlling the disease in the majority of cases. Mortality can occur as a consequence of severe disease or as a result of the therapies that are frequently employed as treatment. Commonly employed therapies include systemic corticosteroids, azathioprine and mycophenolate mofetil. In a small subset of patients, these first- and second-line therapies do not control disease or are not tolerated by the patients. Optional therapies include nicotinamide (niacinamide), tetracycline, intravenous immunoglobulin, cyclophosphamide, dapsone and methotrexate. The majority of BP patients are elderly, and several considerations need to be taken into account before a specific therapy is chosen. Methotrexate provides several advantages in the elderly population in terms of practicality, cost and tolerability. Several retrospective and prospective studies have evaluated its effectiveness in the treatment of BP in the elderly population. The results of these studies indicate that methotrexate is an effective therapy for BP and is a reasonable option for treatment in the elderly population, although maybe not as a first- or second-line therapy.

Keywords: Bullous pemphigoid; Elderly; Methotrexate

Document Type: Leading article

Affiliations: 1: 1 Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA 2: 2 Department of Dermatology, Case Western Reserve University, Cleveland, Ohio, USA

Publication date: 2008-01-01